(±)-13β,17α-二乙基-17β-羟基甾烷骈[3,2-C]吡唑及[2,3-C]呋咱的合成

以(±)-13β,17α-二乙基-17β-羟基-5α-甾烷-3-酮(Ⅱ)为原料,经甲酰化、缩合反应合成了(±)-13β,17α,-二乙基-17β-羟基-5α-甾烷骈[3,2-C]吡唑(Ⅴ);又将甲酰化反应所得羟次甲基化合物(Ⅳ)依次转变成单肟(Ⅵ)、双肟(Ⅶ)、再坏合成(±)-13β,17α-二乙基-5α-甾烷骈[2,3-C]呋咱(Ⅷ)。 采用类似的反应,从(Ⅱ)及(Ⅳ)的5β-异构体(Ⅲ)和(Ⅸ)分别合成了(±)-13β,17α-二乙基-17β-羟基-5β-甾烷骈[3,2-C]吡唑(Ⅹ)与(±)-13β,17α-二乙基-17β-羟基-5β-甾烷骈[2,3-C)呋咱(ⅩⅢ)。     

7α,17α-二甲基-17β-羟基雄甾-4-烯-3酮的若干A环骈杂环衍生物的合成

将7α-甲基引进甲基睾丸素后,经甲酰化反应制得2-羟次甲基衍生物(Ⅳ),再先后转变为单肟(Ⅴ)、双肟(Ⅵ),环合得70,17α-二甲基-17β-羟基-雄甾-4-烯骈[2,3-c]呋咱(Ⅶ)。也可使(Ⅳ)与水合肼或盐酸羟胺作用,分别制得相应的雄甾-4-烯骈[3,2-c]吡唑(Ⅷ)及雄甾2,4-二烯骈[2,3-d]异(口恶)唑(Ⅸ)。在酸性反应条件下合成(Ⅸ)时,还分离出它的重排脱水产物7α,17α,17β-三甲基雄甾-2,4,13-三烯骈[2,3-d]异(口恶)唑(Ⅹ)。     

(±)-13β,17α-二乙基-17β-羟基甾烷骈[3,2-C]吡唑及[2,3-C]呋咱的合成

在改造促蛋白同化甾体药物的化学结构时,曾发现有些A环骈合杂环的雄甾烷,不仅有较高的促蛋白同化活性,还能明显地降低血甘油三酯与胆甾醇,并可不同程度地降低β脂蛋白,例如17α-甲基-17β-羟基-5α-雄甾烷-3-酮的A环骈合〔3,2-C〕吡唑或〔2,3-C〕呋咱,即得合成药物康力龙或去脂舒,它们已被临床用作降血脂药物。从能调整脂蛋白和降低β脂蛋白的药物来寻找降血脂新药是国外近年来研究方面之一。本文选用(±)18,19双失碳17α,13β-二     

17β-羟基-4ɑ,5ɑ-环氧雄甾烷并[2,3-d]异噁唑的合成工艺改进

17β-羟基雄甾-4-烯-3-酮与甲酸乙酯在甲醇钠条件下经缩合生成17β-羟基-2-羟亚甲基雄甾-4-烯-3-酮,与盐酸羟胺环合形成17β-羟基-4-烯-雄甾烷并[2,3-d]异噁唑,最后经m-CPBA环氧化制得曲洛司坦关键中间体17β-羟基-4ɑ,5ɑ-环氧雄甾烷并[2,3-d]异噁唑,总收率为70%,纯度为99.1%。     

应用~(13)C核磁共振INEPT方法测定5α-氯-16-次甲基-3β,6β,17α-三羟基-孕甾-20-酮-3β,17α二醋酸酯的结构

应用质子去偶及质子偶合INEPT方法测定药物合成中间体(Ⅱ)的结构。与宽带质子去偶及门控去偶方法比较,INEPT方法具有较高的灵敏度和选择性,节省实验时间。     

(2β,3α,16β,17β)-3,17-双乙酰氧基-2,16-双哌啶基-5α-雄甾烷的合成

目的合成泮库溴铵和维库溴铵的中间体(2β,3α,16β,17β)-3,17-双乙酰氧基-2,16-双哌啶基-5α-雄甾烷。方法以表雄酮为原料,经磺酰化、消除、乙酰化、环氧化、取代、乙酰化反应合成目标化合物。结果所得产物及中间体经核磁共振谱确认。结论所设计合成路线可行,总收率30.4%,可用于工业生产。     

铀促排药物研究:Ⅳ,N,N′-双-[N-羧甲基-(2,3-二羟基-5-甲氧羰基苄胺乙酰基]-α,ω-二胺的合成

随着核工业的迅速发展,核燃料铀对人类构成了一种潜在威脅。铀在人体脏器内的沉积不但引起损伤,并能诱发肿瘤。关于铀的促排解毒药物,虽有一些报道,但未见在临床应用。作者等曾合成了多个系列新的膦酸类和邻苯二酚类双取代或单取代胺羧酰胺螫合剂,动物试验结果表明其中的大多数排铀效果显著,尤其是邻苯二酚类单取代胺羧酰胺(Ⅰ)中,若干化合物排铀效果远远超过文献报道较多的钛铁试剂和Phosphicine,而且显示了     

1,4-二氢噻吩并[3',2':5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物的合成及抗癌活性研究(英文)

本文以2-巯基噻吩为原料,经6步反应合成了5个1,4-二氢噻吩并[3',2':5,6]噻喃并[4,3-c]吡唑-3-羧酸衍生物,并采用人乳腺癌细胞MCF-7对目标化合物的抗肿瘤活性进行初步评价。所合成化合物在100μM浓度下均有一定的抑制MCF-7活性。     

氧甲氢龙合成中伴生副产物2-(2-羟基乙氧基)-17β-羟基-2,17α-二甲基-A-失碳-5α-雄甾烷的鉴定与合成

目的为改进氧甲氢龙的合成工艺及提高产率提供实验依据。方法通过柱色谱、重结晶等方法分离纯化合成氧甲氢龙过程中发现的副产物,经IR、1H-NMR、13C-NMR、MS、元素分析、X-单晶衍射实验等分析手段确证副产物的化学结构;推测副产物的形成机制并按此机制合成该副产物。结果与结论鉴定副产物为2-（2-羟基乙氧基）-17β-羟基-2,17α-二甲基-A-失碳-5α-雄甾烷,其形成机制可能是格氏试剂形成的甲基负离子在进攻中间体（7）17位的羰基碳的同时,一部分的甲基负离子从甾体平面结构的下方进攻了2位的乙缩酮的碳原子进而生成该副产物。准确分析出副产物的化学结构及形成机制。     

应用13C核磁共振INEPT方法测定5α-氯-16-次甲基-3β,6β,17α-三羟基-孕甾-20-酮-3β,17α二醋酸酯的结构

应用质子去偶及质子偶合INEPT方法测定药物合成中间体(Ⅱ)的结构。与宽带质子去偶及门控去偶方法比较,INEPT方法具有较高的灵敏度和选择性,节省实验时间。     

Reactions with acetoacetanilide: Synthesis and antibacterial activity of some new pyran,pyrano[2,3-c]pyrazole and pyrano[2,3-c]-pyridine derivatives

The reaction of acetoacetanilide (1) with the α-cyanocinnamonitrile derivatives2 yielded the Michael adducts4 which could be converted into the pyrano[2,3-c] pyrazole derivatives5 via their reaction with hydrazine hydrate. Cyclisation of4 afforded the cyanoaminopyrans9 which could in turn be converted into the corresponding pyridine derivatives10. The pyranopyrazoles9 reacted with different activated nitrile derivatives (3a-c) to give the pyrano[2,3-c]pyridine derivatives13, 16 and19 respectively. The biological activity of the synthesised heterocyclic derivatives was investigated and discussed.     

Synthesis and Calcium Antagonistic Activity of 8-[N-[2-(3,4-Dimethoxyphenyl)ethyl]-β-alanyl]-5,6,7,8-tetrahydrothieno[3,2-b][1,4]thiazepine Fumarate

KT-362 is an antiarrhythmic and antihypertensive agent with vasodilating activity. Since it carries a homoveratryl group in the side chain, an obvious relation exists to the verapamil-type calcium antagonists. Replacement of the fused aromatic moiety in KT-362 with thiophene provided 8-[N-[2-(3,4-dimethoxyphenyl)ethyl]-β-analyl]-5,6,7,8-tetrahydrothieno[3,2-b][1,4] thiazepine ( 1 ). Compound 1 shows a negative chronotropic activity in spontaneously beating right atria (IC₅₀ = 23 μM, n = 7), and a negative inotropic effect in papillary muscles (IC₅₀ = 2.7 μM, n = 7) and left atria (IC₅₀ = 4 μM, n = 6) of the guinea-pig heart. The decrease of contractility in papillary muscles could be antagonized by increasing the extracellular calcium concentration. Compound 1 was found to affect high (IC₅₀: 70 ± 5 μM) and low (IC₅₀: 129 ± 34 μM) voltage-activated calcium channel currents as well as voltage-activated sodium channel currents (IC₅₀: 80 ± 13 μM) in chick dorsal root ganglion neurons. In addition, nicotine-induced currents were potently inhibited (IC₅₀: 6 ± 0.7 μM) in bovine chromaffin cells.     

Synthesis and molluscicidal activity of some 1,3,4-triaryl-5-chloropyrazole, pyrano[2,3-c]pyrazole, pyrazolylphthalazine and pyrano[2,3-d]thiazole derivatives

2-(5-Chloro-1,3-diphenyl-1H-pyrazol-4-ylmethylene)-malononitrile 1a reacts with the arylidenes of malononitrile 2a-d to afford the triaryl-5-chloropyrazoles 3a-d, respectively. 1a reacts with the active methylene pyrazolinones 5a, b and 12a, b to afford different products 8, 9, 10, 11, and 14a, b--depending on the substitution in the pyrazole ring. Compound 1a reacts also with the pyridazinone derivative 15 to afford the phthalazinone 16, and with the thiazolinones 17a-c to afford the pyrano[2,3-d]thiazoles 20a-c, respectively. It reacts also with the malononitrile dimer 21a and with ethyl cyanoacetate dimer 21b to yield the pyrazolyl pyridines 22a, b, respectively. The synthesized compounds showed a moderate molluscicidal activity towards Biomphalaria alexandrina snails.     

2-取代-4-氨基噻吩并[3,2-d]嘧啶类化合物的合成及抗增殖活性

目的设计并合成2-取代-4-氨基噻吩并[3,2-d]嘧啶类化合物,评价其体外抗增殖活性。方法以3-氨基-2-噻吩甲酸甲酯为起始原料,经6步反应合成目标化合物;以CP-31398为阳性对照药,采用MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]法测定了目标化合物对肿瘤细胞株H-460和HT-29的抗增殖活性。结果与结论合成16个未见文献报道的化合物,其结构经1H-NMR、MS确证;5个化合物显示较好的抗增殖活性,其中,化合物8n活性突出,为CP-31398的4-5倍。     

3-(氨基烷氧基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物的设计、合成与乙酰胆碱酯酶抑制活性

目的初步探讨在7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物母核C-3位苯环侧链中引入二乙胺基团的3-(氨基烷氧基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物的合成及其乙酰胆碱酯酶抑制活性。方法以取代的苯甲醛和乙酰甘氨酸为初始原料,经Erlenmeyer-Plchl反应、缩合反应、水解反应、缩合反应,生成6-芳甲基-3-硫代-1,2,4-三嗪-5(2H)-酮类化合物,再与取代的α-氯代苯乙酮反应,得到6-芳甲基-3-(羟基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物;以芳基乙烯为原料,经温和的氧化反应、缩合反应得到3,4-二氢-6-芳基-3-硫代-1,2,4-三嗪-5(2H)-酮类化合物,再与取代的α-氯代苯乙酮在乙酸中反应得到6-芳基-3-(羟基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物。两条合成路线得到的3-(羟基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物进一步经Williamson反应制备得到10个3-(烷氧基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物。所有目标化合物结构均经质谱、红外光谱和核磁共振氢谱确证。采用Ellman法对目标化合物进行体外乙酰胆碱酯酶抑制活性筛选。结果根据前期已筛选化合物的活性数据和总结出的初步构效关系,设计并合成了10个C-3位苯环侧链中含有二乙胺基团的3-(氨基烷氧基芳基)-7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物。体外乙酰胆碱酯酶抑制活性筛选表明,所有目标化合物均具有乙酰胆碱酯酶抑制活性,其中7个化合物在10μmol.L-1浓度水平抑制活性超过了50%。结论根据体外重组人源AChE(rhAChE)抑制活性的测试结果,发现C-3位苯环侧链中含有二乙胺基团的7H-噻唑并[3,2-b]-1,2,4-三嗪-7-酮类化合物均具有较好的rh-AChE抑制活性。在这一位置的侧链中引入二乙胺基团,可以增强化合物对rhAChE的抑制活性。     

Synthesis, ultra-short acting hypnotic activity, and metabolic profile of ethyl 8-oxo-5,6,7,8-tetrahydro-thiazolo[3,2-a] [1,3]diazepin-3-carboxylate (HIE-124)

The synthesis and biological evaluation of ethyl 8-oxo-5,6,7,8-tetrahydro-thiazolo[3,2-a][1,3]diazepin-3-carboxylate (HIE-124, 4), as a member of a new generation of ultra-short acting hypnotics is described. HIE-124 4 exhibited potent in-vivo activity with a very rapid onset of action and a shorter duration of action with no acute tolerance or noticeable side effects than thiopental sodium. The rat in-vivo and in-vitro metabolic profile of 4 is also described. Urine was pooled from a number of animals and analyzed using electrospray liquid chromatography mass spectrometry (ESI LC-MS). HIE-124 4 was incubated with rat-liver microsomal and rat-liver hepatocyte preparations then similarly analyzed. The only metabolic product of both in-vitro and in-vivo experiments is the carboxylic acid derivative 5. HIE-124 4 has the potential use not only as a pre-anesthetic medication and as anesthesia inducer but also has the potential to be used with thiopental sodium to maintain anesthesia for longer duration.